当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Aubrey Jarman, Lauren Howard, Pao-Hwa Lin and Stephen J Freedland
We previously completed a 6-month randomized trial of ≤20g carbohydrates/day low carbohydrate diet (LCD) intervention vs. no dietary change in men with a rising prostate specific antigen (PSA) after failed local therapy (CAPS2). Men in the LCD group lost significant weight and exploratory analysis suggested slowed tumor growth as measured by longer PSA doubling time. Though patients were not asked to continue the diet post-study, we hypothesized the benefits of weight loss would encourage men to maintain some level of LCD relative to their pre-study diet. Of the 45 participants who completed the CAPS2 trial, 17 (5 control, 12 LCD) participants completed all on-study and follow-up measurements. The median carbohydrate intake for the LCD group at follow up was slightly lower than that of the control group (145g vs 186g; p=0.8). Caloric, macronutrient intake, weight and BMI were similar between groups at follow-up (all p≥0.2). Men randomized to a 6-month LCD, but not advised to maintain it long-term, tend to revert to their pre-study diet after study completion. Considering the benefits that consuming an LCD may have for PC patients, more effective strategies are needed to ensure long-term behavior change and improve diet adherence.